Europe Pemphigus Vulgaris Treatment Market Research Report: Forecast (2025-2030)

Market Definition

Pemphigus Vulgaris (PV) is a type of autoimmune disease that is rarely found, in which the body’s immune system attacks the skin and mouth linings and results in the formation of fluid-filled, painful blisters and sores.

Market Insights & Analysis: Europe Pemphigus Vulgaris Treatment Market (2025-30):

The Europe Pemphigus Vulgaris Treatment Market size was valued at around USD106.15 million in 2024 and is expected to reach USD169.38 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.10% during the forecast period, i.e., 2025-30. The market is substantially growing, which is stimulated by various factors, including the high prevalence of autoimmune diseases such as Pemphigus Vulgaris (PV) in European countries, the robust research and developments, significant investments by various national governments, the innovation of advanced treatments such as biologic drugs, and biomarker therapies, etc. One of the core reasons for this incidence is the higher genetic predisposition in the European population, which includes genetic factors like Human Leucocyte Antigen (HLA). These genes are proactively responsible for the PV disease in Europe.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Additionally, the governments of France, Germany, the UK, etc. are actively supporting the clinical and pre-clinical trials for advanced therapies and treatments for PV by profoundly investing in these kinds of projects. It is providing potential growth opportunities to the European Pemphigus Vulgaris Market by attracting advancements in treatment procedures. Also, the biologics treatment is gaining popularity in the market due to its high efficiency, efficacy, safety, and quality. Moreover, hospital pharmacies are dominating the market based on the distribution channel segment due to easy retailing and a prime spot for customer preference. This market is specifically dominating in Germany due to having a robust healthcare infrastructure and strong government support.

Furthermore, the identification of biomarkers and personalized therapies & treatments is positively transforming and uplifting the market due to high patient awareness and efficient early detection and treatments. However, the high treatment costs, complicated manufacturing procedures, fragmented supply chain, and controlled storage ensure cold-chain management are some of the challenges faced by the European Pemphigus Vulgaris Market.

Europe Pemphigus Vulgaris Treatment Market Driver:

Increasing Incidence of Pemphigus Vulgaris – Europe has witnessed a rising prevalence of Pemphigus Vulgaris (PV) recently, which has led to the increased demand for improved treatments of this disease. The high burden of PV in Europe is due to various reasons, including environmental exposure, lifestyle changes, and genetic susceptibility. Additionally, acute viral or bacterial infectious agents can act as skin adhesion proteins called desmogleins can cause PV along with severe infections. Also, Europe has one of the highest aging populations, which is highly prone to chronic disorders due to weak immune systems, and PV is an autoimmune disease that requires a strong immune system. For instance, over 21% of the population is aged above 65 years, and more than 70% of PV cases have been found in older people in Europe.

Europe Pemphigus Vulgaris Treatment Market Opportunity:

Increasing Investment in Advanced Biologic Treatments – Europe is continuously improving its healthcare facilities and investing in advanced biologic treatments for rare autoimmune diseases such as PV, which are offering ample opportunities for this market to grow significantly. The national governments of European countries such as the United Kingdom, Germany, France, etc. are substantially allocating funds under various schemes to improve the diagnosis and treatment of such diseases. Many applications for biological licensing have been sent to the regulatory bodies of European countries.  

For instance, the EU4Health Program (2024), allocated USD109 million for the vaccine development and effective biologics, also the Eurostars-2 Program (2021), significantly funded the development of a monoclonal antibody called Proteogenix, targeting the HLA gene causing PV disease, which is under clinical trial and hopefully will get the approval after successful R&D. Additionally, the UK Ministry OF Exchequer (2025) has announced funding of about USD110 billion in the development of biologics for rare diseases like PV. These efforts are contributing to the advanced treatments for PV and increasing the potential growth of the market.

Europe Pemphigus Vulgaris Treatment Market Challenge:

Complex Manufacturing Process & High Cost of Treatment – The drugs for treating PV disease are complex to produce as they require stringent controlled environments for high-quality and purity of drugs. There is a high requirement for sterile conditions to ensure the quality, efficacy, and safety of the drugs. Every new drug development can cost around USD100 million, which forces the companies to arrange a substantial amount of funding for research and development for their specialized drug products. This is leading to a struggle for small biotech companies to enter the market effectively to their full potential.

Additionally, in Europe, a single monoclonal antibody treatment can cost more than USD20,000. It is limiting the accessibility to a large number of patients by putting financial barriers, thus hindering the market’s growth.

Europe Pemphigus Vulgaris Treatment Market Trend:

Personalized Treatment Using Biomarkers – The advanced treatments for PV in Europe are being transformed by the adoption of personalized drugs and biomarker treatments. These methods are providing effective treatments to the affected individuals. The Horizon Europe (2021-2027) program has invested significantly in personalized health care using biomarker-based therapies. For instance, the TAU IMMUNE PROJECT has allocated over USD260,000 for the development of immunotherapies for diseases such as Pemphigus Vulgaris. Additionally, the 3TR project in Europe, with an estimated investment of about USD87 million, identified biomarkers for almost seven autoimmune diseases, including Pemphigus Vulgaris, using a transcriptomics approach. It involved about 70 organizations such as AstraZeneca PLC, GSK, and many more.

Europe Pemphigus Vulgaris Treatment Market (2025-30): Segmentation Analysis

The Europe Pemphigus Vulgaris Treatment Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the regional level. Based on the analysis, the market has been further classified as:

Based on Treatment Type:

• Corticosteroids
• Immunosuppressants
• Biologics
  • Rituximab
  • Intravenous Immunoglobulin (IVIG)
• Antibiotics
• Plasmapheresis

Out of these, the Biologics segment holds the largest market share of about 40%. Biologics are technologically advanced treatments as compared to the traditional ones, including immunosuppressants and corticosteroids. This treatment is highly effective and provides better results and complete suspension of the disease. Additionally, these kinds of therapeutics have negligible side effects, which encourages patients to prefer this treatment.

Among all biologics, Rituximab is the dominant one in Europe, which recently got approved by the regulatory body called the European Medicines Agency (EMA). More than 80% of the individuals suffering from PV have been treated using Rituximab, contributing to the market growth. Moreover, the resilient R&D in the EU countries is increasing the adoption of other biologics such as FcRn inhibitors and Intravenous Immunoglobulin (IVIG), thus increasing the market’s growth.

Based on Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Among these, hospital pharmacies are the most preferred distribution channel, accounting for more than 55% of the market share. The major factor contributing to the market’s growth is the large volume of visits of PV patients to hospitals for check-ups, so they prefer to take proper treatments, including immunosuppressants, etc., from the corresponding hospital pharmacies. Additionally, the trust of customers related to the pharmacies in hospitals is contributing to the segmental revenue growth.

Moreover, some of the medications, including biologics such as rituximab, and IVIG are prescription drugs only in Europe and cannot be self-administered, which are only written in hospitals during the checkups, so it makes it easier for the patients to purchase these from the nearest distribution channel is the hospital pharmacies, thus resulting in maximum market demand from this segment of Pemphigus Vulgaris Market in Europe.

Europe Pemphigus Vulgaris Treatment Market (2025-30): Regional Projections

Geographically, the Europe Pemphigus Vulgaris Treatment Market expands across:

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Germany is leading the European Pemphigus Vulgaris Treatment Industry and holds a market share of about 28%. The supremacy is due to the advanced healthcare facilities in the country. On average, Germany has about 3,000 well-established hospitals, and according to OECD Health data (2023), the country spends about 11% of its GDP on healthcare, which is higher as compared to the mean value of the European Union. For instance, in 2023, Germany spent over USD455 billion just in the healthcare industry. It shows the high dominance of Germany in this market.

Additionally, the country has an extensive presence of biotech pharmacies such as Bayer, Merck KgaA, and many more, supporting the enhancements and improvements in the treatment procedures. Moreover, the country has a strong reimbursement system, which includes the statutory health insurance (SHI) system that covers 90% population for providing reimbursement for approved biologics and advanced therapies, which is contributing to the country’s growth in this market.

Europe Pemphigus Vulgaris Treatment Industry Recent Development:

• 2024: Sanofi S.A. submitted a Biologic Licensing Application (BLA) to the European regulatory body for Dupixent, which has received regulatory attention in Europe, with submissions currently under review by the European Medicines Agency. This follows its designation as an orphan drug by the U.S. FDA for Pemphigus Vulgaris (PV), highlighting its potential as a valuable treatment option. Approval in Europe is highly anticipated, which could provide new hope for patients with PV across the region.

Gain a Competitive Edge with Our Europe Pemphigus Vulgaris Treatment Market Report

1. Europe Pemphigus Vulgaris Treatment Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. Europe Pemphigus Vulgaris Treatment Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.